Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.

Kangyuan Pharmaceutical (600557.SH) announced that the company has recently received the "Drug Clinical Trial Approval Notice" for Qing Shen Tong Luo Granules issued by the National Medical Products Administration. The approval conclusion for Qing Shen Tong Luo Granules is: in accordance with the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the clinical trial application for Qing Shen Tong Luo Granules submitted on January 28, 2026 meets the relevant requirements for drug registration. With further improvement of the clinical trial protocol, it is approved to conduct confirmatory clinical trials (Phase III clinical trials) for the treatment of rheumatoid arthritis with damp-heat obstruction syndrome.